Remote ischemic preconditioning to reduce contrast-induced nephropathy.

Phase 2

Completed

Conditions: contrast-induced kidney injury
contrast-induced nephropathy
10029149

Registration Number: NL-OMON37244

Lead Sponsor: niversitair Medisch Centrum Sint Radboud

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 76

Inclusion Criteria

Inclusioncriteria:
•Interventions with expected intravascular contrast volume > 100 mL:
-Thoracic Endovascular Aortic Repair (TEVAR)
-Endovascular Aortic Repair (EVAR)
-Digital Substraction Angiography (DSA)
-Percutaneous Transluminal Angioplasty (PTA)
-Percutaneous Intentional Endovascular Revascularisation (PIER)
-Carotic Artery Stenting (CAS)
-Percutaneous coiling/embolisation procedures
-Computed Tomographic Angiography

•High-risk of CIN (according CBO guideline):
- eGFR <45ml/min
- eGFR <60ml/min and diabetes
- eGFR <60ml/min ans 2 additional risk factors (peripheral artery disease, heart failure, >75 years, anaemia (Ht<0,39 for men and <0,36 for women), dehydration, use of diuretics and/or NSAID).;•Informed consent

Exclusion Criteria

-Age < 18 years
-Hemo- and peritoneal dialysis
-Concomitant inclusion in another interventional study
-Percutaneous coiling/embolisation procedures of the kidney

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Change in serum creatinine levels from baseline (day prior to contrast<br /><br>administration) to 48 hours after contrast administration.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>-change in biomarkers (for kidney injury) levels in blood and urine from<br /><br>baseline to 24 and/or 48 hours after contrast administration.<br /><br>-incidence of CIN (>25% rise in serum creatinine)<br /><br>-death, rehospitalization and/or hemodialysis within 6 weeks after<br /><br>contrast-administration</p><br>